Reuters -- Amgen's closely watched experimental bone-strengthening drug denosumab helped patients with a mix of advanced cancer types, researchers said on Monday, reinforcing its potential as an alternative to standard therapy.
Reuters -- Amgen's closely watched experimental bone-strengthening drug denosumab helped patients with a mix of advanced cancer types, researchers said on Monday, reinforcing its potential as an alternative to standard therapy.
